Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy

Area of Science:

• Cardiology
• Pharmacology
• Medical Imaging

Background:

• The CAPRICORN trial demonstrated carvedilol's efficacy in patients with left ventricular dysfunction post-myocardial infarction (MI) when treated with ACE inhibitors.
• This substudy investigated carvedilol's impact on left ventricular remodeling in this specific patient cohort.

Purpose of the Study:

• To assess the effects of carvedilol on left ventricular remodeling.
• To determine if changes in remodeling mediate clinical benefits.

Main Methods:

• 127 patients from the CAPRICORN trial underwent quantitative 2D echocardiography.
• Echocardiograms were performed at baseline and at 1, 3, and 6 months after treatment with carvedilol or placebo.
• Left ventricular volumes, ejection fraction (Simpson's method), and wall motion score index were analyzed blindly.

Main Results:

• At 6 months, carvedilol significantly reduced left ventricular end-systolic volume by 9.2 mL compared to placebo (P=0.023).
• Left ventricular ejection fraction was significantly higher by 3.9% in the carvedilol group (P=0.015).
• No significant differences were observed in left ventricular end-diastolic volume or wall motion score index between groups.

Conclusions:

• Carvedilol demonstrated a beneficial effect on left ventricular remodeling in patients with left ventricular dysfunction post-MI treated with ACE inhibitors.
• These remodeling improvements may partially explain the significant clinical benefits observed with carvedilol in this population.